United States Pain Management Therapeutics Market is expected to reach US$ 33.71 Billion by 2030, according to the report. Physical and mental pain has a significant influence on life. It can hinder our daily activities, limit our mobility, and dampen our spirits. Advancements in medical technology and growing awareness have opened up new possibilities in pain management. Medications have traditionally been frequently used in pain treatment to ease or suppress discomfort caused by a variety of disorders. Recognizing the need for new ways, the healthcare sector has focused on the development of pain monitoring devices.United States Pain Management Therapeutics Market was valued at US$ 25.31 Billion in 2022
Pain monitoring devices offer a non-invasive and objective means of assessing an individual's pain experience. By providing healthcare professionals with quantitative data, these devices enable personalized treatment plans and help optimize the effectiveness of pain management strategies. Individuals are becoming more aware of the advantages of pain management devices, especially when compared to opioids, which is boosting demand for these novel solutions. The pharmaceutical industry expansion and innovation in the production of pain-relieving drugs creates potential for the US pain management medication market. Factors such as an increase in pain disorders, improved healthcare infrastructure, and demand for safer and more effective pain drugs are driving market growth. The rising number of health-conscious customers, as well as the incidence of chronic illnesses among the elderly, contributes to the market expansion.
United States Pain Management Therapeutics Market will register a CAGR of 3.65% from 2022 to 2030
Elderly individuals, who often experience chronic pain due to joint disorders and various surgeries, require prescribed pain medications, further driving the growth of the U.S. pain management drug market. The rise in cases of diabetic neuropathies, which lead to pain, also contributes to the market expansion. Educational efforts by various organizations and the government regarding pain disorders and proper pain management play a significant role in raising awareness. With the introduction of e-commerce, companies have gained a vital tool that allows customers to conveniently access products and services.In the context of pain management, health apps and online platforms provide animations and educational resources to inform people about the appropriate dosages and frequencies of pain medications, thereby contributing to the growth of the U.S. pain management drug market. Increased promotional activities by manufacturers and growing awareness among the general population about the proper treatment of pain disorders are expected to fuel the adoption of pain management medications in the future. The area of pain treatment is changing, and the incorporation of new technology and pharmaceuticals offers enormous potential for improving the lives of those who are in pain. The future of pain treatment is brighter, with a focus on personalized methods and a shift away from opioids, bringing hope for a better quality of life for people in need. The United States Pain Management Therapeutics Market was valued at US$ 25.31 Billion in 2022.
United States, pharmaceutical organization performs substantial research, development, and marketing of pain management medications
By Therapeutics, the United States Pain Management Therapeutics Market is segmented into Pharmaceuticals and Devices. The United States pharmaceutical Pain Management Therapeutics Market is a dynamic and rapidly evolving sector within the healthcare industry. As the population ages and chronic pain becomes increasingly common, the demand for effective pain management methods grows. In recent years, there has been a shift in attention toward developing unique and targeted pain management drugs that give more pain relief while lowering the risk of addiction and harmful side effects. As a result, new pharmaceutical items and therapies have entered the market. Advancements in technology and understanding of pain mechanisms drive innovation, such as targeted therapies, precision medicine, and alternative options like medical cannabis. The market is dynamic, aiming to meet the growing demand for effective pain relief. Advancing medications, technology, and treatments holds promise for enhancing the lives of individuals in pain.Neurostimulation has emerged as the fastest-growing segment in the U.S. pain management drug market
By Devices, the United States Pain Management Therapeutics Market is divided into Electrical Stimulators, Radiofrequency Ablation, Analgesic Infusion pumps, and Neurostimulation. Neurostimulation is rapidly gaining momentum in the U.S. pain management drug market. With its implanted devices delivering electrical impulses to nerves, it offers targeted relief for chronic pain conditions. Its effectiveness in reducing pain and improving quality of life has fueled its growth. The market for neurostimulation devices is increasing because they provide a viable alternative to traditional pain drugs, answering the need in the United States for safer and more tailored pain treatment options.Opioids hold the largest share of the United States pain management drug market
By Drug Class, the United States Pain Management Therapeutics Market is classified into Non-steroidal Anti-inflammatory Drugs (NSAIDs), Anesthetics, Anticonvulsants, Anti-migraine Agents, Antidepressants, opiates, and Non-narcotic Analgesics. While opioids are excellent pain relievers, their increasing usage has generated concerns owing to the potential of addiction and other negative side effects. Efforts are being undertaken to address these difficulties through the implementation of tougher restrictions, the promotion of responsible prescription practices, and the investigation of alternative pain management choices. In order to achieve a balance between effective pain relief and reducing the risks associated with opioid use, the market is changing toward safer and more customized medications, as well as non-pharmacological alternatives.Cancer pain is experiencing rapid growth within the U.S. pain management drug market
The Pain Management Therapeutics Market in the United States is classified as Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Post-operative Pain, Migraine, Fibromyalgia, Bone fracture, Muscle sprain or strain, acute appendicitis, and others. With the increased prevalence of cancer cases, there is a greater need for cancer patients to be treated effectively in terms of pain management. Cancer pain management requires a multimodal approach that includes pharmaceutical medicines like opioids and adjuvant medications, as well as non-pharmacological techniques like radiation therapy and nerve blocks. The emphasis is on promoting patient comfort and minimizing the impact of pain on everyday activities. Innovative medicines and pharmaceuticals are being developed to address this crucial part of cancer care as awareness and research in cancer pain management continue to grow.Chronic pain holds the highest market share and is the fastest-growing segment in the U.S. pain management drug market
By Pain Type, the United States Pain Management Therapeutics Market is subdivided into Chronic Pain and Acute Pain. The powerful medications are commonly prescribed for severe acute and chronic pain. With a substantial number of individuals suffering from persistent pain conditions, there is a pressing need for effective management options. The market offers a wide range of pharmaceutical treatments, including opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, and antidepressants, tailored to address different types of chronic pain. Additionally, advancements in technology, such as neurostimulation and targeted therapies, are reshaping the landscape of chronic pain management, providing individuals with new hope for alleviating their pain and improving their quality of life.Online pharmacy market boasts the highest market share and is the fastest-growing segment in the U.S. pain management drug industry
By Distribution Channel, the United States Pain Management Therapeutics Market is broken up into Hospital Pharmacies, Retail pharmacies, and Online Pharmacies. With the convenience and accessibility of online platforms, individuals are increasingly turning to online pharmacies to fulfill their medication needs. Online pharmacies provide a wide choice of pain management pharmaceuticals, allowing people to get pain relief treatments without having to go to a regular pharmacy. The rising popularity of online shopping, along with rising demand for pain management pharmaceuticals, has contributed to the spectacular rise of the online pharmacy business in the US pain management sector.Key Players
Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline plc, Novartis International AG, Merck & Co., Inc., Abbott Laboratories, Johnson & Johnson, and Baxter International Inc. are prominent players in the pain management industry, as highlighted in our analysis. This includes investing in technology innovation to develop advanced pain management solutions, forming partnerships to leverage complementary expertise, expanding their presence in different regions, and engaging in mergers and acquisitions to broaden their product portfolios and market reach.This latest report “US Pain Management Therapeutics Industry, Forecast By Therapeutics (Pharmaceuticals, Devices), Devices (Electrical Stimulators, Radiofrequency Ablation, Analgesic Infusion Pumps, Neurostimulation), Drug Class (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Anesthetics, Anticonvulsants, Anti-Migraine Agents, Antidepressants, Opioids, Nonnarcotic Analgesics), Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Post-Operative Pain, Migraine, Fibromyalgia, Bone Fracture, Muscle Sprain/Strain, Acute Appendicitis and Others), Pain Type (Chronic Pain, Acute Pain), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), Companies (Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline plc, Novartis International AG, Merck & Co., Inc., Abbott Laboratories, Johnson & Johnson and Baxter International Inc)” provides a detailed analysis of US Pain Management Therapeutics Industry.
Therapeutics - Market has been covered from 2 viewpoints:
1. Pharmaceuticals2. Devices
Devices - Market has been covered from 4 viewpoints:
1. Electrical Stimulators2. Radiofrequency Ablation
3. Analgesic Infusion Pumps
4. Neurostimulation
Drug Class - Market has been covered from 7 viewpoints:
1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)2. Anesthetics
3. Anticonvulsants
4. Anti-Migraine Agents
5. Antidepressants
6. Opioids
7. Nonnarcotic Analgesics
Indication - Market has been covered from 11 viewpoints:
1. Arthritic Pai2. Neuropathic Pain
3. Cancer Pain
4. Chronic Back Pain
5. Post-Operative Pain
6. Migraine
7. Fibromyalgia
8. Bone Fracture
9. Muscle Sprain/Strain
10. Acute Appendicitis
11. Others
Distribution Channel - Market has been covered from 3 viewpoints:
1. Hospital Pharmacies2. Retail Pharmacies
3. Online Pharmacies
Pain Type - Market has been covered from 2 viewpoints:
1. Chronic Pain2. Acute Pain
Company Insights:
- Overview
- Recent Development
- Financial Insight
Companies Covered:
1. Eli Lilly and Company2. Pfizer Inc.
3. GlaxoSmithKline plc
4. Novartis International AG
5. Merck & Co., Inc.
6. Abbott Laboratories
7. Johnson & Johnson
8. Baxter International Inc.
What is the estimated value of the U.S. Pain Management Therapeutics Market?
What is the growth rate of the U.S. Pain Management Therapeutics Market?
What is the forecasted size of the U.S. Pain Management Therapeutics Market?
Who are the key companies in the U.S. Pain Management Therapeutics Market?
Report Attribute | Details |
---|---|
No. of Pages | 180 |
Published | August 2023 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 25.31 Billion |
Forecasted Market Value ( USD | $ 33.71 Billion |
Compound Annual Growth Rate | 3.6% |
Regions Covered | United States |
No. of Companies Mentioned | 8 |
Table of Contents
Companies Mentioned
- Eli Lilly and Company
- Pfizer Inc.
- GlaxoSmithKline plc
- Novartis International AG
- Merck & Co., Inc.
- Abbott Laboratories
- Johnson & Johnson
- Baxter International Inc.
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...